In addition, since BRCA2 is a gene for which current guidelines provide specific screening and interventions to reduce the risk of associated cancers, the lack of determination of BRCA2 germline variants in both patients and their relatives has also limited the great potential to facilitate extra-pancreatic cancer prevention in these subjects (Berek et al. 2010; Hartmann et al. 2001; Al-Sukhni et al. 2008). This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.